Objective: To analyze the epidemiological characteristics of growth, as well as factors associated with growth retardation in children with primary nephrotic syndrome (PNS), and to investigate the effect of glucocorti...Objective: To analyze the epidemiological characteristics of growth, as well as factors associated with growth retardation in children with primary nephrotic syndrome (PNS), and to investigate the effect of glucocorticoid (GC) use duration on growth retardation in these children. Methods: Clinical and laboratory data of 353 PNS children treated at our hospital from July 2014 to June 2015 were collected through the medical record management system. Height, weight, and GC usage were recorded. Follow-up assessments were conducted in August 2022 for the original group, recording height, weight, and GC usage. Height and weight were evaluated using standard deviation scores (SDS). Categorical data were analyzed using chi-square test while continuous measurement data were analyzed using t-test or rank-sum test. Linear regression was used to assess the association between two single independent variables, and logistic regression analysis was used to screen for risk factors related to growth retardation in children with PNS. Results: Among the 353 PNS children enrolled in this study, male-to-female ratio of 2.64:1 (256 males vs 97 females). A total of 119 children exhibited growth retardation, incidence rate of 33.71%. The duration of GC usage among those with growth retardation was significantly longer compared to those without it (762.81 ± 934.50 days vs 263.77 ± 420.49 days;p Conclusion: PNS children treated with GC have a high incidence of growth retardation, and a high proportion of short stature in adulthood, especially in children with growth retardation in childhood, most of them have short stature after grown up. Time of GC usage is a risk factor for growth retardation in children with PNS.展开更多
BACKGROUND Primary membranous nephrotic syndrome with chylothorax as the first manifestation is an unusual condition.To date,only a few cases have been reported in clinical practice.CASE SUMMARY The clinical data of a...BACKGROUND Primary membranous nephrotic syndrome with chylothorax as the first manifestation is an unusual condition.To date,only a few cases have been reported in clinical practice.CASE SUMMARY The clinical data of a 48-year-old man with primary nephrotic syndrome combined with chylothorax admitted to the Department of Respiratory and Critical Care Medicine of Shaanxi Provincial People's Hospital were retrospec-tively analysed.The patient was admitted to the hospital for 12 d due to shortness of breath.Imaging showed pleural effusion,laboratory tests confirmed true chylothorax,and renal biopsy revealed membranous nephropathy.After primary disease treatment and early active symptom treatment,the prognosis of the patient was good.This case suggests that chylothorax is a rare complication of primary membranous nephrotic syndrome in adults,and early lymphan-giography and renal biopsy can assist in the diagnosis when there are no contrain-dications.CONCLUSION Primary membranous nephrotic syndrome combined with chylothorax is rare in clinical practice.We report a relevant case to provide case information for clinicians and to improve diagnosis and treatment.展开更多
Objective: To explore better therapy and reduce the rate of re-relapse of primary nephritic syndrome in children who had been treated with corticosteroids but relapsed. Methods: Eighty relapsers were enrolled from Jan...Objective: To explore better therapy and reduce the rate of re-relapse of primary nephritic syndrome in children who had been treated with corticosteroids but relapsed. Methods: Eighty relapsers were enrolled from Jan. 1994 to Apr. 2000, who were randomly divided into two groups. The treatment group (n=39) had been treated with tripterysium glucosides for three months,with the control group (n=41) members were treated with cyclophosphmide (CTX) by intermission intravenous pulse, with total dose of CTX not being more than 150 mg/kg. Prednisone, meanwhile, was given to both groups. The total treatment period of prednisone was prolonged by 12-18 months. Results: After following up for 3-7 years, the re-relapse rates of both groups were observed. The re-relapse rate of the treatment group was 28.2% to 29.3% in the CTX-controlled group. The re-relapse rates between two groups were almost similar, and with no observed significant difference (P>0.05). The side effect of tripterysium glucosides was less than that of CTX. Conclusion: For the treatment of relapsing nephritic syndrome in children, the combination of tripterysium glucosides and prolonged corticosteroid therapy is as effective as the regimen of CTX plus prolonged use of prednisone.展开更多
Objective:To investigate the TCM treatment principle of membranous nephropathy and its effect.Methods:A total of 56 patients were selected from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medi...Objective:To investigate the TCM treatment principle of membranous nephropathy and its effect.Methods:A total of 56 patients were selected from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine.They were then divided into the control group(western medicine standard therapy)and the study group(Qidi Gushen prescription),with 28 patients in each group.The treatment effect,treatment safety,and patients’satisfaction were observed and compared between the two groups.Results:The results showed that the treatment effect of the study group was 96.43%,which was significantly better compared with the control group(75.00%)(p<0.05);in terms of safety,the probability of adverse events was 7.14%in the study group and 32.14%in the control group,in which the difference was statistically significant(p<0.05);in addition,the study group’s satisfaction with the treatment measures was significantly higher than that of the control group(p<0.05).Conclusion:In treating membranous nephropathy,traditional Chinese medicine can be tailored to its pathogenesis,which is not only beneficial to the treatment effect,but also has a high safety profile.展开更多
[Objectives]To observe the clinical efficacy of Shenling Baizhu Powder in the treatment of primary nephrotic syndrome(PNS)featuring damp abundance due to splenic asthenia.[Methods]40 patients with PNS were randomly di...[Objectives]To observe the clinical efficacy of Shenling Baizhu Powder in the treatment of primary nephrotic syndrome(PNS)featuring damp abundance due to splenic asthenia.[Methods]40 patients with PNS were randomly divided into treatment group(n=19)and control group(n=21).In the treatment group and the control group,methylprednisolone tablets were taken orally and cytoxan(CTX)was given intravenously for treatment;in the treatment group,based on oral administration of methylprednisolone tablets and intravenous drip of cytoxan(CTX),oral administration of traditional Chinese medicine(addition and subtraction of Shenling Baizhu Powder)was added.Urine routine,24-hour urinary protein,renal function and serum albumin were re-examined after 4 weeks of treatment.[Results]The total effective rate of the treatment group was significantly higher than that of the control group(89.47%vs 61.90%,P<0.05).After treatment,both groups could effectively reduce the levels of 24-hour urinary protein(P<0.05),serum creatinine(P<0.05)and urea nitrogen(P<0.05),and increase the level of serum albumin(P<0.05),but the degree of improvement in the treatment group was significantly higher than that in the control group(P<0.05),and the difference was statistically significant(P<0.05).[Conclusions]Methylprednisolone combined with addition and subtraction of Shenling Baizhu Powder could effectively reduce urinary protein,improve edema symptoms,shorten the course of hormone use and reduce adverse reactions in the treatment of PNS featuring damp abundance due to splenic asthenia.展开更多
Objective:To explore the effect of sodium ferulate in combined with Huangqi injection on the coagulation and immunological function in patients with primary nephrotic syndrome (PNS).Methods: A total of 137 patients wi...Objective:To explore the effect of sodium ferulate in combined with Huangqi injection on the coagulation and immunological function in patients with primary nephrotic syndrome (PNS).Methods: A total of 137 patients with PNS were included in the study and randomized into the observation group (n=69) and the control group (n=68). The patients in the treatment group were given routine treatment, anticoagulation, lipid regulation, and other symptomatic treatments. On this basis, the patients in the observation group were given sodium ferulate in combined with Huangqi injection. The coagulation, immunological function, and hemorrheology indicators before and after treatment in the two groups were compared.Results:Alb content after treatment in the two groups was significantly elevated when compared with before treatment (P<0.05), while ET, 24 h UPQ, Scr, and BUN levels were significantly reduced when compared with before treatment (P<0.05);moreover, the improvement degree of the above indicators in the observation group was significantly greater than that in the control group (P<0.05). PT and APTT after treatment in the two groups were significantly prolonged when compared with before treatment (P<0.05), while FIB, D-D content, whole blood high shear viscosity, low shear viscosity, blood viscosity, and ARBC were significantly reduced when compared with before treatment (P<0.05);moreover, the improvement degree of the above indicators in the observation group was significantly greater than that in the control group (P<0.05). CD3+, CD4+, and CD8+ after treatment in the two groups were significantly elevated when compared with before treatment (P<0.05). CD3+ and CD4+ after treatment in the observation group were significantly higher than those in the control group (P<0.05). CD4+/CD8+, IgG, and IgA after treatment in the observation group were significantly higher than those in the control group (P<0.05).Conclusions:Sodium ferulate in combined with Huangqi injection in the treatment of PNS can improve the coagulation function and hemorheology, alleviate the blood coagulation, enhance the immunological function, and recover the renal function.展开更多
Objective: To observe the relationship of tumor necrosis factor-o (TNF-a) and nitrogen oxide (NO) with the treatment of frequent relapse nephrotic syndrome (FRNS) and to explore the patho-genesis of FRNS and the thera...Objective: To observe the relationship of tumor necrosis factor-o (TNF-a) and nitrogen oxide (NO) with the treatment of frequent relapse nephrotic syndrome (FRNS) and to explore the patho-genesis of FRNS and the therapeutic mechanism of Shenkangling (肾康灵,SKL) Granule in children. Methods: Sixty children suffering from FRNS were randomly divided into the treated group and control group, 30 in each, and the other 30 healthy children were taken as healthy group. The patients were treated with prednisone for a long-term course, and those with no effect or partial effect shown were treated with additional Tripterygium or Cytoxan in the control group, while in the treated group patients were treated with prednisone and additional SKL. The two groups were compared as to their changes of TNF-a, NO before and after treatment, and the relapses after treatment. Results: The levels of TNF-a and NO in the sick children before treatment were markedly higher than those after treatment and normal group (P< 0. 01). The positive correlation between TNF-o of FRNS cases and relapse risk displayed more significance than that between the relapse of FRNS and NO. The difference between treated group and control group was significant (P<0. 01). Conclusion: TNF-a can be regarded as the monitoring parameter of the active phase in FRNS, and the higher the level, the more possible the relapse would occur. SKL could markedly reduce the relapse rate of FRNS in children.展开更多
目的探讨罗沙司他联合基础疗法治疗原发性肾病综合征(PNS)继发急性肾损伤(AKI)患者的临床效果,以期为PNS继发AKI患者临床治疗方案的选择提供参考。方法选取2022年7月—2023年5月重庆大学附属中心医院收治的118例PNS继发AKI患者,采用随...目的探讨罗沙司他联合基础疗法治疗原发性肾病综合征(PNS)继发急性肾损伤(AKI)患者的临床效果,以期为PNS继发AKI患者临床治疗方案的选择提供参考。方法选取2022年7月—2023年5月重庆大学附属中心医院收治的118例PNS继发AKI患者,采用随机数字表法分为对照组和研究组,每组59例。对照组患者采用基础疗法治疗,研究组患者在对照组基础上联合罗沙司他治疗。比较2组患者的临床疗效,治疗前后的肾功能指标[血清肌酐(SCr)、尿素氮(BUN)、肾小球滤过率(eGFR)]、24 h尿蛋白定量(24 h Upro)、血浆白蛋白、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、血常规指标[白细胞计数(WBC)、红细胞计数(RBC)、血红蛋白(Hb)、血小板计数(PLT)]及肝功能指标[白蛋白(ALB)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)],并进行安全性评估。结果研究组患者的治疗总有效率为91.53%(54/59),高于对照组的77.97%(46/59),差异有统计学意义(χ^(2)=4.196,P=0.041)。2组患者不同治疗时间点的血清SCr、BUN水平及eGFR重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗7 d、14 d及28 d时的SCr、BUN水平均低于同一时间点的对照组,eGFR高于同一时间点的对照组,差异均有统计学意义(P<0.05)。2组患者不同治疗时间点的24 h Upro、血浆白蛋白、TC及TG水平重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗14 d及28 d时的24 h Upro、TC与TG水平均低于同一时间点的对照组,血浆白蛋白水平高于同一时间点的对照组(P<0.05);2组患者治疗前后LDL-C及HDL-C水平比较,差异无统计学意义(P>0.05)。2组患者治疗前及治疗28 d时的WBC、RBC、Hb、PLT、ALB、ALT、AST、TBIL水平比较,差异均无统计学意义(P>0.05)。研究组与对照组患者不良反应发生率分别为3.39%(2/59)和1.69%(1/59),差异无统计学意义(P>0.05)。结论罗沙司他联合基础疗法治疗PNS继发AKI患者的疗效确切,能有效改善患者肾功能与血脂代谢,具有较高的用药安全性,且对患者肝功能影响较小,值得在临床推广。展开更多
文摘Objective: To analyze the epidemiological characteristics of growth, as well as factors associated with growth retardation in children with primary nephrotic syndrome (PNS), and to investigate the effect of glucocorticoid (GC) use duration on growth retardation in these children. Methods: Clinical and laboratory data of 353 PNS children treated at our hospital from July 2014 to June 2015 were collected through the medical record management system. Height, weight, and GC usage were recorded. Follow-up assessments were conducted in August 2022 for the original group, recording height, weight, and GC usage. Height and weight were evaluated using standard deviation scores (SDS). Categorical data were analyzed using chi-square test while continuous measurement data were analyzed using t-test or rank-sum test. Linear regression was used to assess the association between two single independent variables, and logistic regression analysis was used to screen for risk factors related to growth retardation in children with PNS. Results: Among the 353 PNS children enrolled in this study, male-to-female ratio of 2.64:1 (256 males vs 97 females). A total of 119 children exhibited growth retardation, incidence rate of 33.71%. The duration of GC usage among those with growth retardation was significantly longer compared to those without it (762.81 ± 934.50 days vs 263.77 ± 420.49 days;p Conclusion: PNS children treated with GC have a high incidence of growth retardation, and a high proportion of short stature in adulthood, especially in children with growth retardation in childhood, most of them have short stature after grown up. Time of GC usage is a risk factor for growth retardation in children with PNS.
基金Supported by the Shaanxi Provincial People’s Hospital Science and Technology Development Incubation Fund Project,No.2021YJY-33.
文摘BACKGROUND Primary membranous nephrotic syndrome with chylothorax as the first manifestation is an unusual condition.To date,only a few cases have been reported in clinical practice.CASE SUMMARY The clinical data of a 48-year-old man with primary nephrotic syndrome combined with chylothorax admitted to the Department of Respiratory and Critical Care Medicine of Shaanxi Provincial People's Hospital were retrospec-tively analysed.The patient was admitted to the hospital for 12 d due to shortness of breath.Imaging showed pleural effusion,laboratory tests confirmed true chylothorax,and renal biopsy revealed membranous nephropathy.After primary disease treatment and early active symptom treatment,the prognosis of the patient was good.This case suggests that chylothorax is a rare complication of primary membranous nephrotic syndrome in adults,and early lymphan-giography and renal biopsy can assist in the diagnosis when there are no contrain-dications.CONCLUSION Primary membranous nephrotic syndrome combined with chylothorax is rare in clinical practice.We report a relevant case to provide case information for clinicians and to improve diagnosis and treatment.
文摘Objective: To explore better therapy and reduce the rate of re-relapse of primary nephritic syndrome in children who had been treated with corticosteroids but relapsed. Methods: Eighty relapsers were enrolled from Jan. 1994 to Apr. 2000, who were randomly divided into two groups. The treatment group (n=39) had been treated with tripterysium glucosides for three months,with the control group (n=41) members were treated with cyclophosphmide (CTX) by intermission intravenous pulse, with total dose of CTX not being more than 150 mg/kg. Prednisone, meanwhile, was given to both groups. The total treatment period of prednisone was prolonged by 12-18 months. Results: After following up for 3-7 years, the re-relapse rates of both groups were observed. The re-relapse rate of the treatment group was 28.2% to 29.3% in the CTX-controlled group. The re-relapse rates between two groups were almost similar, and with no observed significant difference (P>0.05). The side effect of tripterysium glucosides was less than that of CTX. Conclusion: For the treatment of relapsing nephritic syndrome in children, the combination of tripterysium glucosides and prolonged corticosteroid therapy is as effective as the regimen of CTX plus prolonged use of prednisone.
文摘Objective:To investigate the TCM treatment principle of membranous nephropathy and its effect.Methods:A total of 56 patients were selected from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine.They were then divided into the control group(western medicine standard therapy)and the study group(Qidi Gushen prescription),with 28 patients in each group.The treatment effect,treatment safety,and patients’satisfaction were observed and compared between the two groups.Results:The results showed that the treatment effect of the study group was 96.43%,which was significantly better compared with the control group(75.00%)(p<0.05);in terms of safety,the probability of adverse events was 7.14%in the study group and 32.14%in the control group,in which the difference was statistically significant(p<0.05);in addition,the study group’s satisfaction with the treatment measures was significantly higher than that of the control group(p<0.05).Conclusion:In treating membranous nephropathy,traditional Chinese medicine can be tailored to its pathogenesis,which is not only beneficial to the treatment effect,but also has a high safety profile.
基金Natural Science Research Project of Guangxi University of Chinese Medicine(2015LX037).
文摘[Objectives]To observe the clinical efficacy of Shenling Baizhu Powder in the treatment of primary nephrotic syndrome(PNS)featuring damp abundance due to splenic asthenia.[Methods]40 patients with PNS were randomly divided into treatment group(n=19)and control group(n=21).In the treatment group and the control group,methylprednisolone tablets were taken orally and cytoxan(CTX)was given intravenously for treatment;in the treatment group,based on oral administration of methylprednisolone tablets and intravenous drip of cytoxan(CTX),oral administration of traditional Chinese medicine(addition and subtraction of Shenling Baizhu Powder)was added.Urine routine,24-hour urinary protein,renal function and serum albumin were re-examined after 4 weeks of treatment.[Results]The total effective rate of the treatment group was significantly higher than that of the control group(89.47%vs 61.90%,P<0.05).After treatment,both groups could effectively reduce the levels of 24-hour urinary protein(P<0.05),serum creatinine(P<0.05)and urea nitrogen(P<0.05),and increase the level of serum albumin(P<0.05),but the degree of improvement in the treatment group was significantly higher than that in the control group(P<0.05),and the difference was statistically significant(P<0.05).[Conclusions]Methylprednisolone combined with addition and subtraction of Shenling Baizhu Powder could effectively reduce urinary protein,improve edema symptoms,shorten the course of hormone use and reduce adverse reactions in the treatment of PNS featuring damp abundance due to splenic asthenia.
文摘Objective:To explore the effect of sodium ferulate in combined with Huangqi injection on the coagulation and immunological function in patients with primary nephrotic syndrome (PNS).Methods: A total of 137 patients with PNS were included in the study and randomized into the observation group (n=69) and the control group (n=68). The patients in the treatment group were given routine treatment, anticoagulation, lipid regulation, and other symptomatic treatments. On this basis, the patients in the observation group were given sodium ferulate in combined with Huangqi injection. The coagulation, immunological function, and hemorrheology indicators before and after treatment in the two groups were compared.Results:Alb content after treatment in the two groups was significantly elevated when compared with before treatment (P<0.05), while ET, 24 h UPQ, Scr, and BUN levels were significantly reduced when compared with before treatment (P<0.05);moreover, the improvement degree of the above indicators in the observation group was significantly greater than that in the control group (P<0.05). PT and APTT after treatment in the two groups were significantly prolonged when compared with before treatment (P<0.05), while FIB, D-D content, whole blood high shear viscosity, low shear viscosity, blood viscosity, and ARBC were significantly reduced when compared with before treatment (P<0.05);moreover, the improvement degree of the above indicators in the observation group was significantly greater than that in the control group (P<0.05). CD3+, CD4+, and CD8+ after treatment in the two groups were significantly elevated when compared with before treatment (P<0.05). CD3+ and CD4+ after treatment in the observation group were significantly higher than those in the control group (P<0.05). CD4+/CD8+, IgG, and IgA after treatment in the observation group were significantly higher than those in the control group (P<0.05).Conclusions:Sodium ferulate in combined with Huangqi injection in the treatment of PNS can improve the coagulation function and hemorheology, alleviate the blood coagulation, enhance the immunological function, and recover the renal function.
文摘Objective: To observe the relationship of tumor necrosis factor-o (TNF-a) and nitrogen oxide (NO) with the treatment of frequent relapse nephrotic syndrome (FRNS) and to explore the patho-genesis of FRNS and the therapeutic mechanism of Shenkangling (肾康灵,SKL) Granule in children. Methods: Sixty children suffering from FRNS were randomly divided into the treated group and control group, 30 in each, and the other 30 healthy children were taken as healthy group. The patients were treated with prednisone for a long-term course, and those with no effect or partial effect shown were treated with additional Tripterygium or Cytoxan in the control group, while in the treated group patients were treated with prednisone and additional SKL. The two groups were compared as to their changes of TNF-a, NO before and after treatment, and the relapses after treatment. Results: The levels of TNF-a and NO in the sick children before treatment were markedly higher than those after treatment and normal group (P< 0. 01). The positive correlation between TNF-o of FRNS cases and relapse risk displayed more significance than that between the relapse of FRNS and NO. The difference between treated group and control group was significant (P<0. 01). Conclusion: TNF-a can be regarded as the monitoring parameter of the active phase in FRNS, and the higher the level, the more possible the relapse would occur. SKL could markedly reduce the relapse rate of FRNS in children.
文摘目的探讨罗沙司他联合基础疗法治疗原发性肾病综合征(PNS)继发急性肾损伤(AKI)患者的临床效果,以期为PNS继发AKI患者临床治疗方案的选择提供参考。方法选取2022年7月—2023年5月重庆大学附属中心医院收治的118例PNS继发AKI患者,采用随机数字表法分为对照组和研究组,每组59例。对照组患者采用基础疗法治疗,研究组患者在对照组基础上联合罗沙司他治疗。比较2组患者的临床疗效,治疗前后的肾功能指标[血清肌酐(SCr)、尿素氮(BUN)、肾小球滤过率(eGFR)]、24 h尿蛋白定量(24 h Upro)、血浆白蛋白、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、血常规指标[白细胞计数(WBC)、红细胞计数(RBC)、血红蛋白(Hb)、血小板计数(PLT)]及肝功能指标[白蛋白(ALB)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)],并进行安全性评估。结果研究组患者的治疗总有效率为91.53%(54/59),高于对照组的77.97%(46/59),差异有统计学意义(χ^(2)=4.196,P=0.041)。2组患者不同治疗时间点的血清SCr、BUN水平及eGFR重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗7 d、14 d及28 d时的SCr、BUN水平均低于同一时间点的对照组,eGFR高于同一时间点的对照组,差异均有统计学意义(P<0.05)。2组患者不同治疗时间点的24 h Upro、血浆白蛋白、TC及TG水平重复测量方差分析的组间、时间及交互效应比较,差异均有统计学意义(P<0.05);研究组患者治疗14 d及28 d时的24 h Upro、TC与TG水平均低于同一时间点的对照组,血浆白蛋白水平高于同一时间点的对照组(P<0.05);2组患者治疗前后LDL-C及HDL-C水平比较,差异无统计学意义(P>0.05)。2组患者治疗前及治疗28 d时的WBC、RBC、Hb、PLT、ALB、ALT、AST、TBIL水平比较,差异均无统计学意义(P>0.05)。研究组与对照组患者不良反应发生率分别为3.39%(2/59)和1.69%(1/59),差异无统计学意义(P>0.05)。结论罗沙司他联合基础疗法治疗PNS继发AKI患者的疗效确切,能有效改善患者肾功能与血脂代谢,具有较高的用药安全性,且对患者肝功能影响较小,值得在临床推广。
